Project Grant HT94252510926
Award Date 9/30/25
Completion Date 9/29/29
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kingston, RI 02881, USA
Similar Awards
- This federal Project Grant award of $1,293,748.00, made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to investigate the use of bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. The research will be conducted by the University of Louisville's Office of Research & Innovation over a performance period from September 30, 2025 to...
- The U.S. Defense Health Agency awarded a $715,213 Project Grant to the Veterans Education and Research Association of Northern New England, Inc. (VERANNE) to conduct research on using bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. This award is part of the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research aimed at transforming healthcare for...
- The Defense Health Agency awarded a $1,117,352 Project Grant to Trustees of Boston University's Boston University Medical Campus to develop a novel and practical intervention for detoxification of per- and polyfluoroalkyl substances (PFAS) in humans. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports the university's research to transform health care for Service Members and the public through innovative biomedical research. As part of the...
- This federal Project Grant award of $660,283.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Carnegie Mellon University to develop a high-throughput bioanalytical and machine learning approach for prioritizing bioaccumulative per- and polyfluoroalkyl substances (PFAS) in complex mixtures. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing...
- This $864,533 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Metis Foundation, a non-profit organization based in San Antonio, Texas. The purpose of this 3-year award, with a performance period from September 30, 2025 to September 29, 2028, is to conduct research on the association between PFAS and other toxic military exposures and pancreatic cancer risk in a military population. The Metis Foundation, which...
- This federal Project Grant award, in the amount of $385,219, was provided by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health grant program (CFDA 93.113). The award supports research at the University of Rhode Island to investigate the role of albumin and other serum factors in the accumulation and toxicity of per- and polyfluoroalkyl substances (PFAS). The research aims to determine whether albumin is a key factor for PFAS distribution and...
- This $701,121 federal Project Grant award from the Department of Defense's Defense Health Agency, issued under the Military Medical Research and Development program (CFDA 12.420), supports research on the ovarian-disrupting effects and mechanisms of per- and polyfluoroalkyl substances (PFAS). The project is being conducted by Rutgers, The State University of New Jersey's RBHS-School of Nursing over a 3-year period from September 2023 to September 2026. The research aims to develop a better...
- The University of Illinois was awarded a $798,912 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate how PFAS (per- and polyfluoroalkyl substances) exposures can reprogram prostate stem cells and drive carcinogenesis and cancer progression. The 3-year project, running from July 1, 2023 to June 30, 2026, will advance scientific understanding of how environmental PFAS exposures may...
- The Defense Health Agency awarded a $1,999,583 Project Grant to IRR Inc. under the Military Medical Research and Development program (CFDA 12.420) to conduct an early-stage proof-of-concept study of a fixed-dose combination therapy in a high-fidelity porcine model of severe polytrauma. The performance period for this award runs from July 1, 2025 to June 30, 2027. The purpose of this federal grant is to transform healthcare for military service members, veterans, and the broader public through...
- This $440,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research by Baylor College of Medicine in Houston, Texas to develop biopolymers for intestinal healing and immune modulation to treat inflammatory bowel disease. The award has a performance period from January 15, 2025 to January 14, 2027. The Military Medical Research and Development program supports advanced biomedical research to transform...